ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 06/14/22

Amgen’s Lumakras revenue is ramping rapidly. Amgen Phase 2 topline olpasiran data was positive. Amgen rheumatoid arthritis biosimilar received FDA approval. For further details see: Amgen Compelling On New Data And Biosimilar Approval

The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event. For further details see: Arrowhead Pharmaceuticals (ARWR) Investor Presentation - Slideshow

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conference – June 8-10, 2022 Type: Fireside chat presentation Presenter: Vincent Anzalone, Vice President Finance...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong pivot from my formerly diversified base to a more focused core. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping crea...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecul...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund (the “Fund”) fell sharply and significantly lagged the broader market during the fir...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down 12% in Wednesday afternoon trading despite reporting Q1 2022 results after the closing bell Tuesday that beat on the top and bottom lines. The company swung to a quarterly net gain of ~$44.4M ($0.41 per share, diluted) from a net loss ...

Image source: The Motley Fool. Arrowhead Pharmaceuticals (NASDAQ: ARWR) Q2 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Arrowhead Pharmaceuticals (ARWR) Q2 2022 Earnings Call Transcript...